Complement dependent cytotoxicity (CDC) in chronic lymphocytic leukemia (CLL): Ofatumumab enhances alemtuzumab CDC and reveals cells resistant to activated complement

Complement dependent cytotoxicity (CDC) is an important mechanism of action for monoclonal antibodies (mAb) used in the treatment of chronic lymphocytic leukemia (CLL). We hypothesized that alemtuzumab (ALM) mediated CDC would be increased by addition of ofatumumab (OFA). CLL cells from 21 previousl...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Leuk Lymphoma
Main Authors: Baig, Nisar A., Taylor, Ronald P., Lindorfer, Margaret A., Church, Amy K., LaPlant, Betsy R., Pavey, Emily S., Nowakowski, Grzegorz S., Zent, Clive S.
Format: Artigo
Sprog:Inglês
Udgivet: 2012
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5058513/
https://ncbi.nlm.nih.gov/pubmed/22475085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2012.681657
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker